» Articles » PMID: 29693141

Analysis of NFKB2‑mediated Regulation of Mechanisms Underlying the Development of Hodgkin's Lymphoma

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2018 Apr 26
PMID 29693141
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Nuclear factor‑κB (NF‑κB) is widely involved in various lymphoid malignancies. However, its exact functional role and potential regulatory mechanisms in Hodgkin's lymphoma (HL) remains unclear. The present study aimed to investigate the regulatory mechanism of NF‑κB in HL by analysis of a gene expression profile that was obtained from HL cells with or without NF‑κB subunit 2 (NFKB2) knockdown. The GSE64234 dataset containing 6 HL cell line specimens transfected with small interfering (si)RNA against NFKB2 and 6 control specimens transfected with non‑targeting siRNA sequences was downloaded from the Gene Expression Omnibus database. Based on these data, differentially expressed genes (DEGs) were screened for following data preprocessing. Functional enrichment analysis was subsequently conducted among the identified upregulated and downregulated DEGs. Additionally, a protein‑protein interaction (PPI) network was constructed and module analyses were performed. Finally, microRNAs (miRNAs/miRs) targeting the identified DEGs were predicted for the construction of a miRNA‑target regulatory network. A total of 253 DEGs were identified, consisting of 109 upregulated and 144 downregulated DEGs. Pathway enrichment analysis revealed that B‑cell lymphoma 2‑like 1 (BCL2L1) was significantly enriched in the NF‑κB signaling pathway, and colony‑stimulating factor 2 (CSF2) and BCL2L1 were enriched in the Jak‑signal transducer and activator of transcription (STAT) signaling pathway. BCL2L1 and CSF2 were determined to be hub genes in the PPI network. A total of 6 miRNAs, including let‑7a‑5p, miR‑9‑5p, miR‑155‑5p, miR‑135a‑5p, miR‑17‑5p and miR‑375, were identified in the miRNA‑target regulatory network. The results of the present study indicated that NFKB2 may be involved in HL development through regulation of BCL2L1, CSF2, miR‑135a‑5p, miR‑155‑5p and miR‑9‑5p expression, as well as the modulation of Jak‑STAT and NF‑κB signaling pathways.

Citing Articles

Inborn errors of immunity and its clinical significance in children with lymphoma in China: a single-center study.

Yang C, Li N, Zhang M, Huang S, Jin L, Liu S J Pediatr (Rio J). 2024; 100(4):384-391.

PMID: 38547930 PMC: 11331237. DOI: 10.1016/j.jped.2024.02.002.


Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer.

Han G, Hwang I, Cho H, Ylaya K, Choi J, Kwon H Int J Mol Sci. 2021; 22(11).

PMID: 34071938 PMC: 8198528. DOI: 10.3390/ijms22115714.


Function of Deptor and its roles in hematological malignancies.

Morales-Martinez M, Lichtenstein A, Vega M Aging (Albany NY). 2021; 13(1):1528-1564.

PMID: 33412518 PMC: 7834987. DOI: 10.18632/aging.202462.


Temporal Splicing Switches in Elements of the TNF-Pathway Identified by Computational Analysis of Transcriptome Data for Human Cell Lines.

Genov N, Basti A, Abreu M, Relogio A Int J Mol Sci. 2019; 20(5).

PMID: 30857150 PMC: 6429354. DOI: 10.3390/ijms20051182.

References
1.
Lim K, Yang Y, Staudt L . Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev. 2012; 246(1):359-78. PMC: 4094296. DOI: 10.1111/j.1600-065X.2012.01105.x. View

2.
Neri A, Fracchiolla N, Migliazza A, Trecca D, Lombardi L . The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies. Leuk Lymphoma. 1996; 23(1-2):43-8. DOI: 10.3109/10428199609054800. View

3.
Kanehisa M, Goto S . KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999; 28(1):27-30. PMC: 102409. DOI: 10.1093/nar/28.1.27. View

4.
Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B . Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood. 2009; 114(14):2945-51. DOI: 10.1182/blood-2009-02-204842. View

5.
Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D . Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003; 348(24):2386-95. DOI: 10.1056/NEJMoa022473. View